Campylobacter bacteriophages and uses thereof
AssigneeIntralytix, Inc.
InventorAlexander Sulakvelidze
Life of this patent
Estimating the term…
Abstract
The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Campylobacter species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Campylobacter species in various settings (e.g., food safety, sanitation, modulating microbiome, prebiotics, probiotics).
Claims25
A dietary supplement and/or nutraceutical composition comprising one or more of an isolated bacteriophage CJLB-4 deposited under ATCC Deposit Accession No. PTA-126839, CJLB-5 deposited under ATCC Deposit Accession No. PTA-126840, CJLB-7 deposited under ATCC Deposit Accession No. PTA-126841, CJLB-10 deposited under ATCC Deposit Accession No. PTA-126842, CJLB-12 deposited under ATCC Deposit Accession No. PTA-126843, CJLB-13 deposited under ATCC Deposit Accession PTA-126844, CJLB-14 deposited under ATCC Deposit Accession PTA-126845, CJLB-15 deposited under ATCC Deposit Accession PTA-126846, or a combination thereof, or variants of said bacteriophage which have average nucleotide identity over genome of ≥99.9% relative to said bacteriophage, said variants having lytic activity against Campylobacter species or strains, wherein the dietary supplement and/or nutraceutical composition is formulated as a lyophilized or spray-dried powder, an enteric capsule, or a syrup, wherein the bacteriophage in the syrup is stabilized with an effective amount of an agent selected from the group consisting of:
- a water-soluble polymer or sugar, a derivative of cellulose, a low or medium molecular weight polyvinylpyrrolidone, a glycol with a molecular weight of 4000 or 6000, sodium alginate, a protein, a lipid, a polysaccharide, and a mixture thereof.
A dietary supplement and/or nutraceutical composition comprising one or more of an isolated bacteriophage CJLB-4 deposited under ATCC Deposit Accession No. PTA-126839, CJLB-5 deposited under ATCC Deposit Accession No. PTA-126840, or a combination thereof, or variants of said bacteriophage which have average nucleotide identity over genome of ≥95% relative to said bacteriophage, wherein the composition is formulated as a lyophilized or spray-dried powder, an enteric capsule, or a syrup, wherein the bacteriophage in the syrup is stabilized with an effective amount of an agent selected from the group consisting of:
- a water-soluble polymer or sugar, a derivative of cellulose, a low or medium molecular weight polyvinylpyrrolidone, a glycol with a molecular weight of 4000 or 6000, sodium alginate, a protein, a lipid, a polysaccharide, and a mixture thereof.
A dietary supplement and/or nutraceutical composition comprising one or more of an isolated bacteriophage CJLB-7 deposited under ATCC Deposit Accession No. PTA-126841, CJLB-10 deposited under ATCC Deposit Accession No. PTA-126842, CJLB-12 deposited under ATCC Deposit Accession No. PTA-126843, CJLB-13 deposited under ATCC Deposit Accession PTA-126844, CJLB-14 deposited under ATCC Deposit Accession PTA-126845, CJLB-15 deposited under ATCC Deposit Accession PTA-126846, or a combination thereof, or variants of said bacteriophage which have average nucleotide identity over genome of ≥99.9% relative to said bacteriophage, wherein the composition is formulated as a lyophilized or spray-dried powder, an enteric capsule, or a syrup, wherein the bacteriophage in the syrup is stabilized with an effective amount of an agent selected from the group consisting of:
- a water-soluble polymer or sugar, a derivative of cellulose, a low or medium molecular weight polyvinylpyrrolidone, a glycol with a molecular weight of 4000 or 6000, sodium alginate, a protein, a lipid, a polysaccharide, and a mixture thereof.
Dependencies are inferred from the claim text.